NewsEarningsNorris Medicines Reports Q2 FY26 Loss of Rs 102.86 Lakhs Amid Operational ChallengesNorris Medicines Reports Q2 FY26 Loss of Rs 102.86 Lakhs Amid Operational Challenges
Norris Medicines released unaudited financial results for Q2 FY2025-26, reporting a net loss of Rs 102.86 lakhs and revenue from operations of Rs 200.04 lakhs. The company's financial position shows strain with total assets at Rs 1,348.14 lakhs and negative other equity of Rs 2,582.19 lakhs, indicating significant accumulated losses. The Board of Directors approved these results on November 14, 2025, in compliance with SEBI regulations.
*this image is generated using AI for illustrative purposes only.
Norris Medicines has released its unaudited financial results for the quarter ended September 30, 2025, revealing ongoing operational challenges for the pharmaceutical company.
Financial Performance
The company reported a net loss of Rs 102.86 lakhs for the second quarter of the fiscal year 2025-26. This loss comes alongside revenue from operations of Rs 200.04 lakhs for the same period. The financial position of Norris Medicines shows signs of strain, as evidenced by the following key metrics:
| Financial Metric | Amount (in Rs Lakhs) |
|---|---|
| Revenue from Operations | 200.04 |
| Net Loss | 102.86 |
| Total Assets | 1,348.14 |
| Other Equity | -2,582.19 |
The negative other equity of Rs 2,582.19 lakhs indicates significant accumulated losses, potentially raising concerns about the company's financial health.
Board Approval and Disclosure
The Board of Directors of Norris Medicines convened on November 14, 2025, to review and approve the unaudited financial results. The meeting, which began at 5:00 PM and concluded at 5:30 PM, resulted in the approval of the financial statements for the quarter and half-year ended September 30, 2025.
Regulatory Compliance
In adherence to SEBI regulations, particularly Regulation 30 & 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the company has submitted its financial results to the Bombay Stock Exchange. The results were accompanied by a Limited Review Report from the company's auditors, as required by regulatory standards.
Outlook
The continued losses and negative equity position suggest that Norris Medicines may face challenges in the near term. The pharmaceutical sector often faces various challenges, including regulatory pressures, market competition, and operational costs. Norris Medicines' current financial situation underscores the importance of effective management strategies to navigate these industry-specific hurdles.
As the company moves forward, addressing the underlying causes of its financial difficulties and exploring opportunities for revenue growth and cost optimization will be crucial for its long-term sustainability and potential return to profitability.
Historical Stock Returns for Norris Medicines
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.57% | -6.97% | -5.31% | -9.71% | -38.84% | +223.16% |
16
